| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $120K | -0.8% | -27.3% |
| R&D Expense | $8.2M | -29.2% | -15.0% |
| SG&A Expense | $3.9M | +17.5% | +24.7% |
| Operating Income | -$12.0M | +19.0% | +5.0% |
| Net Income | -$11.3M | +19.3% | +5.0% |
| EPS (Basic) | -$0.17 | +19.0% | +32.0% |
| EPS (Diluted) | -$0.17 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $10.1M | -6.0% | -22.3% |
| Short-term Investments | $50.5M | -16.1% | +13.1% |
| Accounts Receivable | $254K | -51.7% | -58.9% |
| Current Assets | $61.8M | -16.1% | +4.2% |
| Total Assets | $63.8M | -15.8% | +1.4% |
| Current Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$32.0M | — | — |
| Capital Expenditures | $44K | — | — |
| Investing Cash Flow | -$9.4M | — | — |
| Financing Cash Flow | $28K | — | — |
| Free Cash Flow | -$32.0M | — | — |
| +19.0% |
| +32.0% |
| $14.7M |
| -11.8% |
| +17.4% |
| Total Liabilities | $15.0M | -12.5% | +11.0% |
| Stockholders' Equity | $48.8M | -16.7% | -1.2% |